The Japanese MHLW has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations for MM.

The agreement will see international initiatives to fight the next pandemic, but funding remains the weak link.

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio for SSGJ-707.

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

The US FDA has approved Incyte’s Zynyz (retifanlimab-dlwr) in conjunction with carboplatin and paclitaxel (platinum-based ...

In April 2025, the European Medicines Agency (EMA) approved Eisai and Biogen’s Leqembi for early-stage Alzheimer’s disease, ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...